Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,569.00GBp
11:14am BST
Change (% chg)

19.00 (+1.23%)
Prev Close
1,550.00
Open
1,556.60
Day's High
1,569.60
Day's Low
1,550.00
Volume
2,041,137
Avg. Vol
8,826,312
52-wk High
1,724.50
52-wk Low
1,235.20

Select another date:

Thu, Jun 14 2018

Photo

GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

CORRECTED-UPDATE 1-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies - a big win after regulators warned of possible birth defects from one of the two drugs.

CORRECTED-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies.

FDA finds deficiencies in Mylan's generic Advair; shares fall

Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.

UPDATE 2-FDA finds deficiencies in Mylan's generic Advair; shares fall

* Shares fall 4.5 pct after market (Adds analyst comment; updates shares)

FDA finds deficiencies in Mylan's generic Advair

June 13 U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

GSK says vaccine business president to leave by year-end

GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year.

UPDATE 1-GSK says vaccine business president to leave by year-end

June 12 GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year.

GSK says vaccine business president to leave by year-end

June 12 GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year.

BRIEF-GlaxoSmithKline Says Completes Novartis' Consumer Healthcare Buyout

* COMPLETED BUYOUT OF NOVARTIS' 36.5% STAKE IN ITS CONSUMER HEALTHCARE JOINT VENTURE FOR $13 BILLION Source text for Eikon: Further company coverage:

Select another date: